Why is Beryl Drugs falling/rising?

As of 23-Sep, Beryl Drugs Ltd is experiencing a price increase, currently at 23.00, with a change of 0.59 or 2.63% up. Today's performance indicates that the stock has outperformed its sector by 2.98% and has gained after two consecutive days of decline. However, despite this short-term uptick, the stock has shown a negative return of -36.11% over the past year, with profits falling by -37%. The stock is trading at a discount compared to its peers' average historical valuations, and it has a very attractive valuation with a Return on Capital Employed (ROCE) of 11. Nonetheless, the company faces challenges, including weak long-term fundamental strength and a poor EBIT to Interest ratio of 0.86, which may contribute to investor caution.
In the broader market context, Beryl Drugs has underperformed compared to the Sensex, which has generated a return of -3.33% over the past year, while Beryl Drugs' return was significantly worse at -36.11%. In the short term, the stock's performance over the past week shows a decline of -3.60%, contrasting with the Sensex's minor drop of -0.34%. This indicates that while there may be some positive momentum in the stock's price today, the overall trend remains concerning, particularly when considering its long-term performance relative to the market.